Defining Factors that Influence vaccine-induced, cross-variant neutralizing antibodies for SARS-CoV-2 in Asians

Abstract

The scale and duration of neutralizing antibody responses targeting SARS-CoV-2 viral variants represents a critically important serological parameter that predicts protective immunity for COVID-19. In this study, we present longitudinal data illustrating the impact of age, sex and comorbidities on the kinetics and strength of vaccine-induced neutralizing antibody responses for key variants in an Asian volunteer cohort. We demonstrate a reduction in neutralizing antibody titres across all groups six months post-vaccination and show a marked reduction in the serological binding and neutralizing response targeting Omicron compared to other viral variants. We also highlight the increase in cross-protective neutralizing antibody responses against Omicron induced by a third dose (booster) of vaccine. These data illustrate how key virological factors such as immune escape mutation combined with host factors such as age and sex of the vaccinated individuals influence the strength and duration of cross-protective serological immunity for COVID-19.

SHEAR saliva collection device augments sample properties for improved analytical performance

“…Saliva samples of each volunteer were aliquoted into two parts and processed with SHEAR SCD and commercial SCD. Exactly, 4.5 μl of SARS‐CoV‐2 nucleocapsid protein (1 μg/μl) 47 and 95.5 μl of ART buffer solution were added to 500 μl of each processed saliva sample and a control solution ‐ phosphate buffer saline solution (PBS). The mixture was vortexed for 1 s, and five drops were loaded onto the sample well of the ART cassette.…”

SHEAR Saliva Collection Device Augments Sample Properties for Improved Analytical Performance

“…500µl of saliva was extracted from each aliquot and processed with SHEAR SCD and commercial SCD (MicroCollect™ Saliva Collection Device, CD Genomics, USA). 1µg/ml SARS-CoV-2 nucleocapsid protein solution were prepared by diluting the 9.5 mg/mL stock solution ( 47 ). 4.5µl of SARS-CoV-2 nucleocapsid protein (1µg/µl) and 95.5ul of Panbio buffer solution were added into each processed saliva sample and a control solution - phosphate buffer saline solution (PBS).…”